Polyphor Ltd – Product Pipeline Review

Global Markets Direct’s, ‘Polyphor Ltd – Product Pipeline Review – 2016’, provides an overview of the Polyphor Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Polyphor Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Polyphor Ltd

The report provides overview of Polyphor Ltd including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Polyphor Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Polyphor Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Polyphor Ltd’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Polyphor Ltd

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Polyphor Ltd’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Polyphor Ltd Snapshot 6

Polyphor Ltd Overview 6

Key Facts 6

Polyphor Ltd - Research and Development Overview 7

Key Therapeutic Areas 7

Polyphor Ltd - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Polyphor Ltd - Pipeline Products Glance 14

Polyphor Ltd - Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

Polyphor Ltd - Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Discovery Products/Combination Treatment Modalities 17

Polyphor Ltd - Drug Profiles 18

balixafortide - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

POL-5551 - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

POL-6014 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

POL-6926 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

POL-7001 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

POL-7080 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

POL-7080 Follow-On - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Small Molecules for Unspecified Indication - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Synthetic Peptides for Unspecified Indication - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Synthetic Peptides to Agonize FPR1/2 for Immunology and Infectious Disease - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Synthetic Peptides to Antagonize FPR1/2 for Immunology and Infectious Disease - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Polyphor Ltd - Pipeline Analysis 31

Polyphor Ltd - Pipeline Products by Target 31

Polyphor Ltd - Pipeline Products by Route of Administration 32

Polyphor Ltd - Pipeline Products by Molecule Type 33

Polyphor Ltd - Pipeline Products by Mechanism of Action 34

Polyphor Ltd - Dormant Projects 35

Polyphor Ltd - Discontinued Pipeline Products 36

Discontinued Pipeline Product Profiles 36

POL-7080 36

Polyphor Ltd - Locations And Subsidiaries 37

Head Office 37

Appendix 38

Methodology 38

Coverage 38

Secondary Research 38

Primary Research 38

Expert Panel Validation 38

Contact Us 38

Disclaimer 39

List of Tables

List of Tables

Polyphor Ltd, Key Facts 6

Polyphor Ltd – Pipeline by Indication, 2016 9

Polyphor Ltd – Pipeline by Stage of Development, 2016 10

Polyphor Ltd – Monotherapy Products in Pipeline, 2016 11

Polyphor Ltd – Partnered Products in Pipeline, 2016 12

Polyphor Ltd – Partnered Products/ Combination Treatment Modalities, 2016 13

Polyphor Ltd – Phase II, 2016 14

Polyphor Ltd – Phase I, 2016 15

Polyphor Ltd – Preclinical, 2016 16

Polyphor Ltd – Discovery, 2016 17

Polyphor Ltd – Pipeline by Target, 2016 31

Polyphor Ltd – Pipeline by Route of Administration, 2016 32

Polyphor Ltd – Pipeline by Molecule Type, 2016 33

Polyphor Ltd – Pipeline Products by Mechanism of Action, 2016 34

Polyphor Ltd – Dormant Developmental Projects,2016 35

Polyphor Ltd – Discontinued Pipeline Products, 2016 36

List of Figures

List of Figures

Polyphor Ltd – Pipeline by Top 10 Indication, 2016 8

Polyphor Ltd – Pipeline by Stage of Development, 2016 10

Polyphor Ltd – Monotherapy Products in Pipeline, 2016 11

Polyphor Ltd – Pipeline by Target, 2016 31

Polyphor Ltd – Pipeline by Route of Administration, 2016 32

Polyphor Ltd – Pipeline by Molecule Type, 2016 33

Polyphor Ltd – Pipeline Products by Mechanism of Action, 2016 34

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports